Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.520
+0.050 (2.02%)
At close: Nov 22, 2024, 4:00 PM
2.500
-0.020 (-0.80%)
After-hours: Nov 22, 2024, 6:45 PM EST
Esperion Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ESPR stock have an average target of 8.17, with a low estimate of 2.50 and a high estimate of 16. The average target predicts an increase of 224.21% from the current stock price of 2.52.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ESPR stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +534.92% | Nov 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +534.92% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +534.92% | Oct 2, 2024 |
| Needham | Needham | Strong Buy Maintains $8 → $6 | Strong Buy | Maintains | $8 → $6 | +138.10% | Aug 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +534.92% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
346.93M
from 116.33M
Increased by 198.22%
Revenue Next Year
436.55M
from 346.93M
Increased by 25.83%
EPS This Year
-0.28
from -2.03
EPS Next Year
0.15
from -0.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 485.3M | 698.0M | 1.0B | ||
| Avg | 346.9M | 436.6M | 522.6M | ||
| Low | 304.3M | 353.1M | 326.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 317.2% | 101.2% | 130.7% | ||
| Avg | 198.2% | 25.8% | 19.7% | ||
| Low | 161.6% | 1.8% | -25.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.09 | 1.43 | 2.36 | ||
| Avg | -0.28 | 0.15 | 0.62 | ||
| Low | -0.42 | -0.47 | -0.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 1,497.4% | ||
| Avg | - | - | 320.9% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.